Responses to ALK Inhibitor Treatments in a Patient with Non-Small Cell Lung Cancer Harboring a Novel HPCAL1-ALK Fusion Variant: A Case Report

Anaplastic lymphoma kinase (ALK) fusion is present in approximately 2–7% of patients with lung adenocarcinoma. ALK fusion-positive patients can benefit from targeted therapy. We herein report a 53-year-old Chinese male patient diagnosed as lung adenocarcinoma with a smoking history. Next-generation...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ruixiao, Qin, Jiayue, Fan, Yafeng, Li, Zhimin, Chen, Chongjian, Su, Wenzhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234975/
https://www.ncbi.nlm.nih.gov/pubmed/32523354
http://dx.doi.org/10.2147/OTT.S252210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234975/
https://www.ncbi.nlm.nih.gov/pubmed/32523354
http://dx.doi.org/10.2147/OTT.S252210

Ejemplares similares